ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Nintedanib (Nintedanib Viatris)

Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old… Show the full indication

Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).

Generic
CHMP opinion 19 Jun 2025 → EU licence 22 Aug 2025 · Viatris Limited

Research

Respiratory · Ann Am Thorac Soc · 2026-09-01

Single-centre target-trial emulation in 172 nintedanib initiators with fibrosing ILD: starting at 100 mg vs 150 mg twice daily was associated with 52.9 more days on treatment over 12 months and lower discontinuation risk (0.135 vs 0.281); FVC change was similar but imprecise.

RCTn = 172
Kaburaki et al. Low-dose vs standard-dose nintedanib at initiation in fibrosing interstitial lung disease: a target-trial emulation of treatment persistence and lung function

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.